Bausch Health, Alfasigma resolve Xifaxan litigation with Sun PharmaSalix will maintain market exclusivity for Xifaxan (rifaximin) 200 mg and 550 mg tablets until 2028. SPARC licenses commercialization rights of Elepsia XR to Tripoint TherapeuticsTripoint will commercialize SPARC's Elepsia XR tablets for five years, with the option to extend the agreement further. FDA letter sets back Hikma's generic Advair Diskus Hikma said it now expects to receive FDA approval for its generic Advair Diskus in early 2021. Lupin intros generic Depakote ER Divalproex sodium ER tablets had a market value of approximately $130 million, according to IQVIA July 2020 data. Zydus Cadila obtains FDA green light for generic K-Dur Zydus Cadila’s generic K-Dur will be available in dosage strengths of 750 mg and 1,500 mg. Dr. Reddy’s settles Revlimid patent litigation with Celgene Dr. Reddy's will be able to sell volume-limited amounts of generic lenalidomide capsules after March 2022, and an unlimited volume beginning Jan. 31, 2026. Zydus Cadila gets FDA OK for generic Doxil liposome injection Liposomal doxorubicin injection had a market value of approximately $124 million for the 12 months ended July 2020, according to IQVIA. Strides Pharma gets FDA OK for generic Meticorten Prednisone tablets have a market value of roughly $12 million, according to IQVIA July 2020 data. Hikma obtains favorable court ruling for generic Vascepa Vascepa has a market value of approximately $1.1 billion for the 12 months ended July 2020. Hikma launches generic Vidaza Azacitidine for injection had a market value of approximately $82 million for the 12 months ended July 2020, according to IQVIA. First Previous 138 139 140 141 142 Next Last
